Evidence for the prevention of enthesitis in HLA-B27/hβ 2m transgenic rats treated with a monoclonal antibody against TNF-α

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 2, 2011, Pages 270-279

  Milia, Anna Franca ^a   Ibba Manneschi, Lidia ^a   Manetti, Mirko ^a   Benelli, Gemma ^a   Generini, Sergio ^a   Messerini, Luca ^a   Matucci Cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Enthesis; HLA B27 transgenic rats; IBD; Smad1 5 8; SpA; Spondyloarthritis; TNF

Indexed keywords

BETA 2 MICROGLOBULIN; HLA B27 ANTIGEN; MADH9 PROTEIN, RAT; MONOCLONAL ANTIBODY; SMAD1 PROTEIN; SMAD1 PROTEIN, RAT; SMAD5 PROTEIN; SMAD5 PROTEIN, RAT; SMAD8 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; ENTERITIS; GENETICS; IMMUNOLOGY; METABOLISM; RAT; TRANSGENIC RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS; BETA 2-MICROGLOBULIN; HLA-B27 ANTIGEN; INFLAMMATORY BOWEL DISEASES; RATS; RATS, TRANSGENIC; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS;

EID: 79951900615     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00984.x     Document Type: Article

References (23)

1. Hammer RE, Maika SD, Richardson JA, et al Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta2m: an animal model of HLA-B27-associated human disorders. Cell. 1990; 63: 1099-112.
2. Taurog JD, Maika SD, Simmons WA, et al Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol. 1993; 150: 4168-78.
3. Breban M. Animal models and in vitro models for the study of aetiopathogenesis of spondyloarthropathies. Baillieres Clin Rheumatol. 1998; 12: 611-26.
4. Rath HC, Herfarth HH, Ikeda JS, et al Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest. 1996; 98: 945-53.
5. Taurog JD, Richardson JA, Croft JT, et al The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994; 180: 2359-64.
6. Keith JC Jr, Sainz IM, Isordia-Salas I, et al A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat. Arthritis Res Ther. 2005; 7: R769-76.
7. Peterson RL, Wang L, Albert L, et al Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest. 1998; 78: 1503-12.
8. 2-microglobulin transgenic rats. J Gastroenterol Hepatol. 2002; 17: 854-60.
9. Bertrand V, Quéré S, Guimbaud R, et al Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin. Eur Cytokine Netw. 1998; 9: 161-70.
10. Taurog JD, Maika SD, Satumtira N, et al Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev. 1999; 169: 209-23.
11. Hacquard-Bouder C, Ittah M, Breban M. Animal models of HLA-B27-associated diseases: new outcomes. Joint Bone Spine. 2006; 73: 132-8.
12. Breban M, Hacquard-Bouder C, Falgarone G. Animal models of HLA-B27-associated diseases. Curr Mol Med. 2004; 4: 31-40.
13. Braun J, Bollow M, Neure L, et al Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995; 38: 499-505.
14. Braun J, Baraliakos X, Listing J, et al Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007; 57: 639-47.
15. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther. 2009; 11: 221.
16. Milia AF, Manetti M, Generini S, et al TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats. J Cell Mol Med. 2009; 13: 164-76.
17. Lories RJ, Luyten FP. Bone morphogenetic protein signalling in joint homeostasis and disease. Cytokine Growth Factor Rev. 2005; 16: 287-98.
18. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005; 115: 1571-9.
19. McGonagle D, Lories RJ, Tan AL, et al The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007; 56: 2482-91.
20. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998; 352: 1137-40.
21. Tran TM, Dorris ML, Satumtira N, et al Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum. 2006; 54: 1317-27.
22. Lories RJ, Derese I, De Bari C, et al Evidence for uncoupling of inflammation and joint remodelling in a mouse model of spondylarthritis. Arthritis Rheum. 2007; 56: 489-97.
23. Sieper J, Appel H, Braun J, et al Critical appraisal of assessment of structural damage in Ankylosing Spondylitis: Implications for treatment outcomes. Arthritis Rheum. 2008; 58: 649-56.